

Novartis therapy Gilenya[®]; reduced the risk of MS disability progression regardless of treatment history or disease severity, new analysis shows

Apr 11, 2011

Source URL: <https://prod1.novartis.com/us-en/news/media-releases/novartis-therapy-gilenyatm-reduced-risk-ms-disability-progression-regardless-treatment-history-or-disease-severity-new-analysis-shows-0>

List of links present in page

1. <https://prod1.novartis.com/us-en/us-en/news/media-releases/novartis-therapy-gilenyatm-reduced-risk-ms-disability-progression-regardless-treatment-history-or-disease-severity-new-analysis-shows-0>